Varenicline is NOT FDA-approved for smokeless (oral) tobacco cessation
Varenicline is FDA-approved exclusively for smoking cessation, not for smokeless tobacco use. The FDA drug label explicitly states that "Varenicline is a nicotinic receptor partial agonist indicated for use as an aid to smoking cessation treatment" 1. There is no mention of smokeless or oral tobacco in the approved indications.
Why This Matters Clinically
The distinction is important because:
- Regulatory approval is specific to cigarette smoking - All major guidelines (NCCN 2016, Mayo Clinic 2009, Canadian Cardiovascular Society 2025) recommend varenicline specifically for smoking cessation, not smokeless tobacco 2, 3, 4
- Off-label use would be required for smokeless tobacco cessation, which means prescribing outside the FDA-approved indication
What the Research Shows (Off-Label Context)
While not FDA-approved for this use, research has examined varenicline for smokeless tobacco:
- A 2016 meta-analysis of 3 RCTs (n=744) found varenicline increased 7-day abstinence at 12 weeks (48% vs 33%, RR=1.45, p<0.0001) but this effect was NOT sustained at 26 weeks (49% vs 39%, p=0.11) 5
- A 2014 Indian trial showed varenicline was safe but had mixed efficacy results for smokeless tobacco users 6
Clinical Bottom Line
For smokeless tobacco cessation, you must use varenicline off-label. The evidence suggests short-term benefit but questionable long-term efficacy. If prescribing off-label:
- Use standard smoking cessation dosing (0.5 mg titrated to 1 mg twice daily for 12 weeks)
- Combine with behavioral counseling
- Monitor closely as the durability of effect beyond 12 weeks is unproven for smokeless tobacco
- Consider NRT as an alternative, which may be more appropriate for oral tobacco users
The safest recommendation is to use FDA-approved NRT products or behavioral counseling as first-line for smokeless tobacco cessation, reserving varenicline for refractory cases where the off-label use is clearly discussed with the patient.